Insider trading

Period: 120 months Stock: GNLX Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

36 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

36 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

36 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

36 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
36 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
36 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

36 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
30 Aug 2024
Szalay Aladar 10% owner · indirect
Sold at will
$309.85K 142,589 at 2.17
15.4%
Not planned
29 Aug 2024
Szalay Aladar 10% owner · indirect
Sold at will
$211.96K 107,045 at 1.98
10.4%
Not planned
27 Aug 2024
Szalay Aladar 10% owner · indirect
Sold at will
$108.86K 51,630 at 2.11
4.7%
Not planned
1 May 2024
Szalay Aladar 10% owner · indirect
Sold at will
$109.16K 33,061 at 3.30
2.7%
Not planned
16 Apr 2024
Szalay Aladar 10% owner · indirect
Sold at will
$171.80K 48,683 at 3.53
3.5%
Not planned
15 Dec 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 2×
$428.18K 32,535 at 13.16
100%
Sold half or more
13 Dec 2023
Thomas John Director
Sold at will 2×
$120.39K 9,000 at 13.38
1.9%
Not planned
13 Dec 2023
Tyree James L Director
Sold at will 2×
$118.97K 9,000 at 13.22
72.2%
Sold half or more
7 Dec 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$436.00K 36,800 at 11.85
53.1%
Sold half or more
21 Nov 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$191.56K 18,665 at 10.26
21.2%
Not planned
20 Nov 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$164.26K 14,594 at 11.26
14.2%
Not planned
25 Oct 2023
Szalay Aladar 10% owner · indirect
Sold at will
$110.64K 5,704 at 19.40
0.4%
Not planned
23 Oct 2023
Szalay Aladar 10% owner · indirect
Sold at will
$998.37K 49,987 at 19.97
3.5%
Not planned
10 Oct 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 2×
$114.46K 5,200 at 22.01
4.7%
Not planned
5 Oct 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$355.23K 14,251 at 24.93
1.0%
Not planned
3 Oct 2023
Szalay Aladar 10% owner · indirect
Sold at will
$1.93M 75,690 at 25.49
5.0%
Not planned
27 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will
$275.46K 11,257 at 24.47
0.7%
Not planned
26 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 3×
$709.18K 29,805 at 23.79
1.9%
Not planned
26 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 3×
$122.53K 5,200 at 23.56
4.7%
Not planned
25 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 4×
$321.00K 12,458 at 25.77
0.8%
Not planned
22 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$247.12K 9,042 at 27.33
0.6%
Not planned
21 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$214.88K 7,549 at 28.46
0.5%
Not planned
20 Sep 2023
Ryder Sean General Counsel
Sold at will
$300.00K 10,000 at 30.00
94.6%
Sold half or more
20 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$167.79K 6,000 at 27.96
5.4%
Not planned
19 Sep 2023
Szalay Aladar 10% owner
Sold at will 2×
$850.94K 32,167 at 26.45
100%
Sold half or more
18 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$705.65K 30,292 at 23.29
85.8%
Sold half or more
15 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 2×
$227.63K 10,400 at 21.89
8.9%
Not planned
14 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$557.81K 25,276 at 22.07
41.7%
Not planned
13 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$629.93K 29,800 at 21.14
21.9%
Not planned
13 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$408.09K 19,032 at 21.44
23.9%
Not planned
12 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$451.17K 20,265 at 22.26
20.3%
Not planned
11 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$718.70K 32,351 at 22.22
24.5%
Not planned
8 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 3×
$575.33K 24,831 at 23.17
15.8%
Not planned
7 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$303.27K 12,446 at 24.37
7.3%
Not planned
30 Aug 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$489.06K 19,800 at 24.70
12.7%
Not planned
18 Aug 2023
Zindrick Thomas President and CEO
Sold at will
$198.12K 8,349 at 23.73
36.3%
Not planned
Showing 1–36 of 36.